Company news

Arvinas, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Arvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership

April 2, 2023

Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

February 22, 2023

Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)

November 21, 2022

Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 7, 2022

Arvinas to Present at Upcoming Conferences

October 31, 2022

Arvinas Announces Winner of the 2022 Arvinas Early Career Researcher Award

October 26, 2022

Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs

October 2, 2022

Arvinas Gives Back to Local Greater New Haven Community

September 29, 2022

Arvinas to Present at Bank of America Securities Precision Oncology Conference

September 25, 2022

Arvinas Appoints Lisa Sinclair as Senior Vice President, Corporate Operations

August 14, 2022

Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 3, 2022

Arvinas Appoints John Northcott as Chief Commercial Officer

July 31, 2022

Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference

June 1, 2022

Arvinas Launches Global Early Career Researcher Award and Announces Call for Nominations

May 31, 2022

GNS Healthcare and Arvinas Enter into Neuroscience Drug Discovery Collaboration

May 8, 2022

Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 4, 2022

Arvinas to Present at Bank of America Securities 2022 Healthcare Conference

May 2, 2022

Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

February 27, 2022

Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer

February 16, 2022

Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting

February 13, 2022

Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer

December 9, 2021

Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium

November 18, 2021

Arvinas to Present at Stifel 2021 Virtual Healthcare Conference

November 9, 2021

Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 2, 2021

Arvinas to Participate in Upcoming Virtual Investor Conferences

August 31, 2021

Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 4, 2021

Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471

July 21, 2021

Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven

June 6, 2021

Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference

June 2, 2021

Arvinas to Present at the UBS Global Healthcare Virtual Conference

May 19, 2021

Arvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven

May 3, 2021

Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 3, 2021

Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021

April 4, 2021

Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

February 28, 2021

Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day

February 7, 2021

Arvinas, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares

December 27, 2020

Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock

December 14, 2020

Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110

December 13, 2020

Arvinas, Inc. Announces Proposed Offering of Common Stock

December 13, 2020

Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC® Protein Degrader Development Programs

December 10, 2020

Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 4, 2020

Arvinas Announces Pipeline Programs Targeting Validated and Classically “Undruggable” Disease-Causing Proteins

October 13, 2020

Arvinas to Present at the 3rd Annual Targeted Protein Degradation Summit

October 5, 2020

Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference

September 3, 2020

Arvinas to Present at the 2020 Wedbush PacGrow Virtual Healthcare Conference

August 6, 2020

Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update

August 3, 2020

Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors

June 28, 2020

Arvinas to Present Virtually at the BMO 2020 Prescriptions for Success Healthcare Conference

June 16, 2020

Arvinas Appoints Linda Bain to its Board of Directors

June 10, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 8 calls. Every call is listed under its year.

Decks

The 5 newest of 19 decks. Every deck is listed under its year.